Intracoronary Tenecteplase versus Abciximab as Adjunctive Treatment during Primary Percutaneous Coronary Intervention in Patients with Anterior Myocardial Infarction.

CONCLUSIONS: Intracoronary administration of tenecteplase did not reduce infarct size compared to abciximab in STEMI patients undergoing PPCI. Tenecteplase exhibited poorer myocardial reperfusion and might be associated with increased subacute stent thrombosis. PMID: 30418157 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research